G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials
Medicinal Research Reviews · 2025
DOI: 10.1002/med.22096 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2025. Verfasst von Aina Bellver-Sanchis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Histone-Lysine N-Methyltransferase, Epigenesis, Genetic, Drug Discovery. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 319 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI; to Christian Griñán-Ferré and Mercè….
Abstract (Originalsprache)
This review provides a comprehensive overview of the role of G9a/EHMT2, focusing on its structure and exploring the impact of its pharmacological and/or gene inhibition in various neurological diseases. In addition, we delve into the advancements in the design and synthesis of G9a/EHMT2 inhibitors, which hold promise not only as a treatment for neurodegeneration diseases but also for other conditions, such as cancer and malaria. Besides, we presented the discovery of dual therapeutic approaches based on G9a inhibition and different epigenetic enzymes like histone deacetylases, DNA methyltransferases, and other lysine methyltransferases. Hence, findings offer valuable insights into developing novel and promising therapeutic strategies targeting G9a/EHMT2 for managing these neurological conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Barcelona, Spain.
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad, India.
- Department of Pharmacy, Central University of Rajasthan, Ajmer, India.
- Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch, South Africa.
- Department of Chemistry, National Institute of Technology Durgapur, Durgapur, India.
- Instituto de Salud Carlos III, Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
ORCID-Profile: Christian Griñán-Ferré
Förderung
- This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI; to Christian Griñán-Ferré and Mercè…
Zitieren
APA
Bellver-Sanchis, A., Ribalta-Vilella, M., Irisarri, A., Gehlot, P., Choudhary, B. S., Jana, A., Vyas, V. K., Banerjee, D. R., Pallàs, M., Guerrero, A., & Griñán-Ferré, C. (2025). G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials. Medicinal Research Reviews. https://doi.org/10.1002/med.22096
Vancouver
Bellver-Sanchis A, Ribalta-Vilella M, Irisarri A, Gehlot P, Choudhary BS, Jana A, et al. G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials. Medicinal Research Reviews. 2025. doi:10.1002/med.22096
BibTeX
@article{BellverSanchis2025,
author = {Bellver-Sanchis, Aina and Ribalta-Vilella, Marta and Irisarri, Alba and Gehlot, Pinky and Choudhary, Bhanwar Singh and Jana, Abhisek and Vyas, Vivek Kumar and Banerjee, Deb Ranjan and Pallàs, Mercè and Guerrero, Ana and Griñán-Ferré, Christian},
title = {G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials},
journal = {Medicinal Research Reviews},
year = {2025},
doi = {10.1002/med.22096}
}
EUVIMED